Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review

Paul Loubet (1, 2) , Charles Burdet (3, 1) , William Vindrios (2) , Nathalie Grall (1, 4) , Michel Wolff (5) , Yazdan Yazdanpanah (1, 2) , Antoine Andremont (1, 4) , Xavier Duval (1, 6) , François-Xavier Lescure (1, 2)

1 IAME (UMR_S_1137 / U1137) - Infection, Anti-microbiens, Modélisation, Evolution
2 Service des maladies infectieuses et tropicales
3 DEBRC - Département d’Epidémiologie, de Biostatistique et de Recherche Clinique [AP-HP Hôpital Bichat - Claude Bernard]
4 Service de Bactériologie [Bichat]
5 Unité de Soins Intensifs et de Maladies Infectieuses
6 CIC Hôpital Bichat

Anti-staphylococcal penicillins (ASPs) are recommended as first-line agents in methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia. Concerns about their safety profile have contributed to the increased use of cefazolin. The comparative clinical effectiveness and safety profile of cefazolin versus ASPs for such infections remain unclear. Furthermore, uncertainty persists concerning the use of cefazolin due to controversies over its efficacy in deep MSSA infections and its possible negative ecological impact.

Mots clés: Staphylococcus aureus; Bacteraemia; Cefazolin; Cloxacillin; Efficacy; Safety

Domaines: Bio-Informatique, Biologie Systémique [q-bio.QM]

Paul Loubet, Charles Burdet, William Vindrios, Nathalie Grall, Michel Wolff, et al.. Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review. Clinical Microbiology and Infection, 2017, ⟨10.1016/j.cmi.2017.07.003⟩. ⟨hal-01597992⟩